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Propagation of oestrogen receptor-positive and
oestrogen-responsive normal human breast cells
in culture
Agla J. Fridriksdottir1,2,*, Jiyoung Kim1,2,*, Rene´ Villadsen1,2,*, Marie Christine Klitgaard1,2,3,
Branden M. Hopkinson1,2, Ole William Petersen1,2 & Lone Rønnov-Jessen3
Investigating the susceptibility of oestrogen receptor-positive (ERpos) normal human breast
epithelial cells (HBECs) for clinical purposes or basic research awaits a proﬁcient cell-based
assay. Here we set out to identify markers for isolating ERpos cells and to expand what appear
to be post-mitotic primary cells into exponentially growing cultures. We report a robust
technique for isolating ERpos HBECs from reduction mammoplasties by FACS using two cell
surface markers, CD166 and CD117, and an intracellular cytokeratin marker, Ks20.8, for
further tracking single cells in culture. We show that ERpos HBECs are released from growth
restraint by small molecule inhibitors of TGFb signalling, and that growth is augmented
further in response to oestrogen. Importantly, ER signalling is functionally active in ERpos cells
in extended culture. These ﬁndings open a new avenue of experimentation with normal ERpos
HBECs and provide a basis for understanding the evolution of human breast cancer.
DOI: 10.1038/ncomms9786 OPEN
1 Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, DK-2200 Copenhagen N, Denmark. 2 Danish Stem
Cell Centre, Faculty of Health Sciences, University of Copenhagen, DK-2200 Copenhagen N, Denmark. 3 Department of Biology, University of Copenhagen,
DK-2100 Copenhagen Ø, Denmark. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to
L.R.-J. (email: lronnov-Jessen@bio.ku.dk).
NATURE COMMUNICATIONS | 6:8786 | DOI: 10.1038/ncomms9786 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
U
nderstanding the taxonomy and evolution of breast
cancer has always relied heavily on the use of normal
cell types as reference (for review see ref. 1). Nevertheless,
ever since the ﬁrst protocol for cultivation of normal human
breast epithelial cells appeared three decades ago2, it has become
increasingly clear that there are no protocols that support
propagation of oestrogen receptor-positive (ERpos) cells. Thus,
along with the appreciation of epithelial cell lineages in the
human breast, primarily the luminal lineage and the basal/
myoepithelial lineage, it became evident that the fastest growing
cells in culture are of basal origin3,4. Moreover, when it was
revealed that ERpos cells in situ accounted for an average of about
7% (mean 6.6%, ranging from 1.2 to 19.1% in a series of
15 normal breast samples) of the cells within the luminal
epithelial lineage5, the chances of recovering these cells in culture
without prospective isolation would in many cases be elusive.
Thus, in culture medium that allowed luminal cells to be
maintained after passaging, endogenous ER expression
disappeared6,7. Likewise, even when employing freshly isolated
small pieces of breast tissue, including the surrounding stroma
thus preserving tissue architecture, steroid receptor expression is
eventually lost8,9. As a consequence of this, the comparison of
cancer with ‘normal’, for example, the HMT-3522, MCF10A and
184B5 cell lines1,6,10, in cell-based assays has relied on normal
cells lacking ER expression.
In an attempt to overcome the loss of receptor expression, ER
has been ectopically introduced into such cell lines. This
approach, however, has had a number of shortcomings, for
example, instead of responding to oestrogen by increased
proliferation as expected, the ER-transfected cells under standard
culture conditions show growth inhibition11,12. Accordingly,
most of our current knowledge of ER expression, regulation and
action comes from breast carcinoma cell lines, whose relation to
ERpos normal breast cells at best remains speculative.
Here we ﬁrst identify the ERpos cells in situ and search for
markers that allow their subsequent tracking in culture. We then
describe culture conditions for primary ERpos cells in the
presence of small-molecule inhibitors of transforming growth
factor-beta (TGFb) signalling. Importantly, these conditions also
yield ERpos cells from luminal ERneg progenitors but not from
basal cells. We envision that the present protocol will serve to
bridge the existing gap of knowledge between normal human
breast, which contain a small pool of ERpos cells and the
overwhelming ER expression found in the majority of breast
cancers.
Results
Identiﬁcation and isolation of normal ERpos HBECs. To answer
the long-standing question of whether loss of hormone receptors
in culture is due to the loss of cells or the loss of receptor protein
expression, it was necessary ﬁrst to provide tools for cell tracking
and sorting of the relevant cells. To unequivocally track ERpos
HBECs at the single-cell level we screened our antibody library
for surrogate markers with a long half-life, for example, cyto-
keratins13, in culture. In situ staining of more than 30 reduction
mammoplasties revealed a surprising pattern with a monoclonal
antibody (clone Ks.20.8) originally raised against cytokeratin 20, a
simple epithelial cytokeratin with a very restricted expression
pattern and not expressed in normal human breast14. The lack of
true cytokeratin 20 expression in normal breast was here
conﬁrmed with two speciﬁc antibodies (listed in Table 1).
Instead, Ks20.8 stained a subpopulation of luminal cells in a
unique scattered pattern (Fig. 1a). Ks20.8 antibodies from four
different suppliers (Table 1) revealed similar staining patterns
(Supplementary Fig. 1a). The characteristic staining pattern led us
to speculate that it indeed represented ERpos cells. While ER and
Ks20.8 apparently co-localized in acini as well as in ducts
Table 1 | List of antibodies used for immunostaining and/or FACS analysis.
Antibody Clone Company/Catalogue No. Peroxidase Fluorescence FACS
AP2b — Santa Cruz, sc-8976 — 1:50 —
BCL2 124 Dako, M0887 — 1:25 —
CDw75 LN1 NeoMarkers, MS-130-P — 1:10 —
CD117 104D2 Dako, M7140 — 1:50 —
CD117 K44.2 Sigma, K0131 — 1:50 —
CD117, PE 104D2 BD Biosciences, 332785 — — 1:20
CD166 3A6 BioLegend, 343902 — 1:50 —
CD166, Alexa Fluor 488 3A6 AbD Serotec, MCA1926A488 — — 1:20
CD271, APC ME20.4 Cedarlane, CL10013APC — — 1:50
CD326, PerCP/Cy5.5 9C4 BioLegend, 324214 — — 1:10–1:20
TGFbRII MM0056–4F14 Abcam, ab78419 — — 1:20
ERa SP1 Labvision, RM-9101-S 1:25 1:10 —
ERa SP1 Labvision, RM-9101-R7 Prediluted, ready to use — —
ERa 1D5 Dako, M7047 1:100 1:25 —
GATA3 HG3–31 Santa Cruz, sc-268 — 1:25 —
Keratin 8 M20 Abcam, ab9023 1:50 1:50 —
Keratin 8 TS1 Novocastra, NCL-CK8-TS1 1:50 — —
Keratin 20* Ks20.8 Dako, M7019 1:25 1:10 —
Keratin 20* Ks20.8 Dako, IR777 Prediluted, ready to use — —
Keratin 20* Ks20.8 Abcam, ab854 1:10 — —
Keratin 20* Ks20.8 Genemed, 61–0018–2 1:25 — —
Keratin 20* Ks20.8 Santa Cruz, SC-52320 1:25 — —
Keratin 20 IT-Ks20.10 Progen Biotechnik, 61054 1:25 — —
Keratin 20 CK205 Novocastra, NCL-CK20–543 1:50 — —
Keratin 8/18 NCL-5D3 Abcam, ab90102 — 1:50 —
Keratin 14 LL002 NeoMarkers, MS-115-P 1:300 1:25 —
Keratin 15 LHK15 NeoMarkers, MS-1068-P — 1:25 —
Keratin 18 M9 Monosan, MON3006 1:100 — —
N-cadherin 32 BD Transduction Laboratories, 610920 — 1:25 —
PR SAN27 Vector Laboratories, VP-P987 1:100 1:25 —
PR SP2 Labvision, RM-9102-S — 1:10 —
PR PgR 636 Dako, M356901–2 1:50 1:10
67-kDa laminin receptor MLuC5 Abcam, ab3099 — 1:50 1:50
*Originally described to recognize cytokeratin 20, but keratin 20 is not expressed in normal human breast14.
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(Supplementary Fig. 1b), the immunoﬂuorescence staining was
not sufﬁciently strong to allow quantiﬁcation. For this purpose, it
was necessary to apply dual antibody immunoﬂuorescence. Since
ER and progesterone receptor (PR) are expressed coordinately in
essentially the same cells in the normal human breast15, we
decided to enhance immunoﬂuorescence staining of uncultured
cells by mixing antibodies for ER and PR. This approach revealed
that the scattered staining with Ks20.8 encompassed almost the
entire population of hormone receptor-positive HBECs in acini as
well as in ducts (Fig. 1b) with the most evident co-localization in
foci with the strongest receptor expression (in four out of eight
biopsies tested). The antibody screen unravelled a number
of additional markers of Ks20.8pos HBECs some of which are
well-known markers of ERpos cells, including activating
enhancer-binding protein 2 beta (AP2b), a marker of luminal
differentiation, GATA3 (ref. 16), a marker of cell survival/
longevity, Bcl2, two TGFb-mediated, epithelial–mesenchymal
transition-related markers, N-glycan/CDw75 antigen17 and N-
cadherin (reviewed in ref. 18), as well as the stem cell markers,
ALCAM (CD166) (ref. 19) and the laminin receptor, 67LR (ref.
20; Supplementary Fig. 2).
For cell sorting purposes we found that CD166 and CD117
made good candidate surface markers of potential ERpos and
ERneg cells, respectively—again as revealed by enhanced multi-
colour immunoﬂuorescence (Fig. 1c). The mutual exclusivity of
CD117 and ER (Fig. 1c) conﬁrms what has been reported by
others21. Accordingly, we designed a ﬂuorescence-activated cell
sorting (FACS) protocol to ﬁrst separate the basal cell population
from the luminal cell population based on EpCAM (CD326)
and NGFR (CD271) followed by sorting with CD166 and
CD117 to further dissect the luminal compartment (Fig. 2a and
Supplementary Fig. 3). This protocol yields three populations, the
purity of which was assessed by staining smears with lineage
and progenitor markers K14, K18 and K15 (ref. 22), ER–PR
as well as the novel ERpos cell surrogate marker Ks20.8 (Fig. 2a).
As expected, we found that ERpos/PRpos HBECs were
highly enriched in the CD166high/CD117low gate (Fig. 2b).
While immunoﬂuorescence staining for ER alone evoked a
cytoplasmic background staining, which prevented reliable
quantiﬁcation, the smears turned out to be ideal for accurate
assessment of the level of co-localization of ER–PR and Ks20.8.
Indeed, up to 90% of Ks20.8pos cells were also ER–PRpos
(Supplementary Fig. 4) and up to 87% of ER–PRpos cells were
Ks20.8pos. The separation of the three subpopulations was further
validated by quantitative reverse transcription–PCR (qRT–PCR),
which conﬁrmed a high ER expression (ESR1) in the CD166high
cells compared with the other subpopulations (Fig. 2c). An
additional panel of markers further distinguished the two luminal
subpopulations from the basal cell population (Supplementary
Fig. 5). Importantly, we found that known ER signalling-related
genes such as trefoil factor family-1 (TFF1; ref. 23) and growth
regulation by oestrogen in breast cancer 1 (GREB1; ref. 24) were
highly expressed in CD166high cells as compared with other
HBECs (Supplementary Fig. 5). The degree of separation in the
CD166/CD117 FACS analysis was, however, somewhat biopsy
dependent. In a series of six biopsies originating from women
between 19 and 44 years old, ﬁve exhibited a similar separation
with 11–49% of the cells being CD166high/CD117low, while one
biopsy apparently did not contain a CD117high population
(Supplementary Fig. 6). As an alternative, CD117 could be
replaced with the laminin receptor 67LR in the CD166 FACS to
obtain enriched ERpos HBECs (80% increase in Ks20.8-positive
cells in the 67LRhigh gate versus the 67LRlow gate; Supplementary
Fig. 7). In conclusion, the combination of Ks20.8, CD166 and
CD117 is a promising marker for ERpos HBEC tracking and
sorting.
ER protein is lost in culture. With the surrogate markers in hand
we were now able to examine the behaviour of sorted ERpos
HBECs in culture, potentially irrespective of ER expression. From
the point of view that favourable conditions for luminal epithelial
cells also apply to ERpos HBECs, we reﬁned a protocol to permit
ample colony formation of luminal cells at clonal density. As cell
culture plastic we used Primaria, a substrate with a high content
of nitrogen previously shown to promote adhesion of breast
cells25. The growth medium ‘FAD2’ was modiﬁed from
previously described media for culturing keratinocytes or basal
breast epithelium on mouse ﬁbroblast feeders26,27. The basal
medium is Ham’s F12:DMEM (1:3) similar to that of Tan et al.27,
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Figure 1 | A unique staining signature Ks20.8pos/CD166high/CD117low is
eligible for ERpos cell sorting and tracking. (a) Serial cryostat sections of a
normal human breast terminal duct lobular unit (TDLU) stained with
immunoperoxidase against Ks20.8 (left) and K18 (right), and
counterstained with haematoxylin. Note the characteristic scattered
staining pattern with Ks20.8 against the uniform lineage-related staining of
luminal cells with K18. Scale bar, 50mm. (b) Multicolour imaging of normal
human breast cryostat sections including acini and ducts from four different
biopsies stained for Ks20.8 (red), hormone receptors ER–PR (SP1–SP2,
green) and DAPI nuclear stain (blue). The Ks20.8pos compartment
encompasses the ER–PR-expressing cells. Scale bar, 50mm. (c) Multicolour
imaging of normal human breast cryostat sections stained for CD166 (3A6,
red), CD117 (K44.2, red), hormone receptors ER–PR (green) and DAPI stain
(blue). While CD166 is highly expressed in hormone receptor-positive cells,
CD117 shows the complementary pattern. Scale bar, 50mm.
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but with less serum, that is, 5%, as in Liu et al.26 Under these
conditions, we gauged for colony formation among the three
FACS gated populations described above. When plated at a clonal
density of 400 cells per cm2, indeed colony forming luminal cells
from the CD117high gate were highly favoured over basal cells
(Fig. 3a). However, it was also clear that the ERpos HBECs from
the CD166high gate entirely failed to form colonies under similar
conditions. However, a scrutiny of cultures at a higher
magniﬁcation revealed that CD166high cells in fact did not
disappear from the culture. Rather, they plated, survived and also
stained with Ks20.8 as a testimony of their original identity, but
they entirely refrained from growth and rapidly lost the ER
protein (Fig. 3b). By comparison, other HBEC culture media, that
is, M87A (ref. 28), MEGM or WIT-P-NC did not support plating
of CD166high cells. Therefore, we conclude that failure of
culturing ERpos HBECs is caused by both lack of growth and
loss of ER expression under conditions otherwise favouring
propagation of luminal epithelial cells.
TGFb inhibitors induce ER expression and release ERpos
HBECs. We noted that earlier in vivo studies had implicated
TGFb1 signalling in the restraint of ERpos mammary epithelial
cells29,30. Here we therefore examined three small inhibitor
molecules of TGFb signalling, RepSox, SB431542 and SD208, and
combinations hereof for their ability to relieve a potentially
negative regulation of ERpos HBEC growth in culture. We found
that dual inhibition with SB431542 and RepSox, hereafter
collectively termed TGFbR2i, recapitulated ER expression and
stimulated ERpos HBEC colony formation in four out of four
biopsies. Moreover, the cells maintained Ks20.8 reactivity, albeit
more widespread than ER expression compared with what is seen
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Figure 2 | ERpos cells are puriﬁed and tracked by sequential CD326/CD271–CD166/CD117 FACS followed by multicolour staining and qRT–PCR.
(a) Multicolour ﬂow cytometry of uncultured HBECs incubated with CD326/CD271/CD166/CD117 and visualized pairwise (left diagrams) to recover
luminal cells (CD326high) and basal cells (CD271high) and from the luminal gate CD166high and CD117high cells. Smears of sorted cells were stained (right
panel) with either of the markers against basal cells, cytokeratin K14; luminal cells, cytokeratin K18; luminal progenitors, cytokeratin K15; Ks20.8 or ER–PR
and counterstained with DAPI nuclear stain. Hormone receptor-positive cells are observed primarily among CD166high cells. Scale bar, 50mm. (b) Purity of
sorted cells as determined by staining of smears followed by quantiﬁcation of the percentage of cells stained with either of the markers cytokeratin K14,
K18, K15, Ks20.8 or hormone receptors (ER–PR; 3 100 cells per slide, error bars indicate s.d.’s). (c) Heatmap representing qRT–PCR analysis of the
relative gene expression of lineage markers in sorted basal cells (basal), CD117high luminal cells (CD117) and CD166high luminal cells (CD166) from six
different biopsies. Data conﬁrm lineage-speciﬁc transcriptional proﬁles of the three cell populations and restricts ER expression (ESR1) primarily to
CD166high luminal cells. Colour bar indicates the fold difference of the relative gene expression in log2 scale.
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in situ (Fig. 4a). ERpos cells from three different biopsies in low-
density primary cultures in TGFbR2i (4,000 cells per cm2)
exhibited a clonal capacity of 0.54%, 0.33% and 0.43%,
respectively. By comparison, control conditions resulted in
small, mostly abortive ERneg clones (Fig. 4b). In general, ER
expression was particularly evident in the dense centre of
proliferating colonies or at conﬂuency. Two different sources of
SP1 antibody gave similar results (Table 1). Moreover, staining
was conﬁrmed with the less-sensitive ER antibody 1D5 (ref. 31).
The response to TGFbR inhibitors was reproducibly observed in
10 out of 10 biopsies.
In addition to ER, TGFbR2i induced the expression of keratin
K8 and the luminal cell transcription factors forkhead box protein
A1, FOXA1 and E74-like factor 5, ELF5 (for reviews, see
refs 32,33) as revealed at the transcriptional level (Fig. 4c). This
expression pattern was conﬁrmed using another biopsy. TGFbR2i
also upregulated the transcription of a number of genes known to
be downstream targets of ER or modulators of ER activity, such as
TFF1 (ref. 23) and insulin growth factor-binding protein 5
(IGFBP5; ref. 34; Supplementary Fig. 8a). Moreover, induction of
ER protein expression to a signiﬁcant degree was speciﬁc to
RepSox as twice the concentration of SB431542 or replacement
of RepSox with another ALK5 kinase inhibitor SD208 was
insufﬁcient to induce K8 and ER (data not shown). RepSox alone
was not as effective in inducing ER or PR as in combination with
SB431542 (Supplementary Fig. 8b). Likewise, while SB431542
alone was capable of inducing increased expression of ER at the
mRNA level (Fig. 4c), this translated to the protein level to a
signiﬁcant degree only in the presence of RepSox (Fig. 4d and
Supplementary Fig. 9). These ﬁndings suggest that ER expression
is controlled through speciﬁc inhibition of TGFb signalling. The
presence of TGFbR in HBECs as well as the inhibition of
phosphorylated SMAD2 concurrent with inhibitor-induced ER
expression supported this (Supplementary Fig. 10 and Fig. 4d).
Indeed, TGFbR2i culture was a key to sustained ER protein
expression as removal of TGFbR2i led to complete loss of ER
protein expression as observed in four independent experiments.
Thus, in a representative experiment the frequency of ERpos cells
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Figure 3 | Loss of ERpos cells in culture is due to both lack of growth
and down modulation of ER expression. (a) T25 ﬂasks in triplicate of
basal cells (basal), CD117 high and CD166high ERpos luminal cells plated at a
clonal density of 104 cells per ﬂask (400 cells per cm2) and stained
with haematoxylin after 14 days in culture. Note that only CD117high cells
are colony forming at clonal density. (b) A higher magniﬁcation of
cultures started at a higher cell density (3,000 cells per cm2) and
immunoperoxidase stained at day 9 for Ks20.8 (upper row) or ER (SP1
prediluted, lower row; inset shows positive staining for ER at day 1 after
plating) and counterstained with haematoxylin. Whereas ER expression is
rapidly lost, the non-colony-forming cells of the CD166high cultures remain
Ks20.8 positive and traceable in culture. Scale bar, 50mm.
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Figure 4 | Relief of TGFb-mediated negative regulation of growth
releases ERpos cells from quiescence. (a) Phase contrast micrographs (left
column) after 8 days in culture and immunoperoxidase staining with
Ks20.8 (middle column) and ER (SP1 prediluted, right column) of primary
cultures of CD166high-derived cells in FAD2 (upper panel) or TGFbR2i
(lower panel). Nuclei are counterstained with haematoxylin. Whereas
Ks20.8pos cells remain quiescent and ER negative on FAD2, they are colony
forming and ER positive in TGFbR2i. Scale bar, 50mm. (b) Quantiﬁcation at
day 13 of ERpos (closed bar) or Ks20.8pos (open bar) colony-forming units
(CFUs) derived from CD166high/CD117low cells from three consecutive
biopsies (p957, p958 and p959) in FAD2 or TGFbR2i. In all three cases
TGFbR2i supplied throughout 9–11 days supported colony formation of
Ks20.8pos/ERpos cells. (c) qRT-PCR of ER (ESR1), K8 (KRT8), FOXA1, ELF5
and K18 (KRT18) of RNA extracted from second-passage cells cultured for
5 days in FAD2 (open bars), in FAD2 with SB421543 (shaded bars) and in
TGFbR2i (solid bars), respectively. Note the collective upregulation of ER
and ER-associated gene expression in TGFbR2i. Error bars indicate s.d. of
three technical triplicates. (d) Western blotting of proteins extracted at day
6 from second-passage CD166high/CD117lowcells seeded at 4,000 cells per
cm2 all cultured without EGF in FAD2 (left lane), in FAD2 with SB421543
(middle lane) and in TGFbR2i (right lane), respectively, incubated with
antibodies recognizing phosphorylated SMAD2 (upper panel), SMAD2/3
(second panel), ER (third panel) and b-actin (lower panel). TGFbR2i inhibits
pSMAD2 and upregulates ER protein expression.
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was reduced from 33.7% (s.d.±5.0%; 3 100 cells) in continuous
TGFbR2i culture to 10.7% (s.d.±0.5%) after 3 days and to 0%
after 5 days without TGFbR2i.
We next tested whether TGFbR2i would induce de novo ER
expression in other subpopulations of luminal cells, for example,
in the much more frequent CD117high-derived HBECs. Con-
sistent with the presumed progenitor status of CD117high cells in
the human breast35, clones emerged from CD117high cells that
gained ER and stained positively for Ks20.8. This was, however,
the only additional source we found of ERpos HBECs, since
TGFbR2i failed to induce ER in basal cells, in breast ﬁbroblasts or
in the established normal cell breast lines MCF10A or HMT-
3522. Thus, both from preexisting ERpos HBECs and from ERneg
progenitors, TGFbR2i readily provides growing colonies of ERpos
HBECs.
TGFbR2i allows growth of ERpos HBECs in serial subculture.
TGFbR2i appeared to support growth of ERpos HBECs also
after passaging. To test this systematically, we plated CD166high-
derived cells at a density of 6,400 cells per cm2 in primary
culture, and the cultures were subsequently passaged at a
density of 4,000 cells per cm2. On passaging, ER expression was
particularly evident in the dense centre of proliferating colonies.
Continuous proliferation under these conditions was maintained
for up to six passages, corresponding to 15 population doublings
(exempliﬁed in Fig. 5a). Importantly, however, in the absence of
RepSox, the cells could not be expanded beyond fourth passage
(Fig. 5a). The lifespan and ER expression (ranging from 21 to
77% in second- to fourth-passage cultures, Table 2) were some-
what biopsy dependent, and in general proliferation slowed
between fourth and sixth passages, and at the same time down-
regulation of ER expression was observed. While this narrowed
the window of experimentation to up to fourth passage, the cells
could easily and reproducibly be replaced with new cultures with
similar luminal characteristics (Table 2). However, passage
number could be increased by increasing seeding density. Thus,
ERpos cells derived from three biopsies could be cultured for
another two to three passages, that is, up to passage six to nine
when passaged at a high density of 8,000–20,000 cells per cm2.
Moreover, the lifespan of ERpos HBECs passaged at low seeding
density could be further extended by initial plating on 3T3 fee-
ders, which lead to proliferation for more than 10 passages,
corresponding to more than 25 population doublings (Fig. 5a).
Cells from a different sorting exhibited similar characteristics
(Fig. 5a). We subsequently addressed whether TGFbR2i culture
would allow for alternative approaches to extend the lifespan of
normal breast-derived ERpos cells. ERpos HBECs were successfully
transduced with pBABE-neo-hTERT and pLenti X2 hygro/shp16
constructs and have now been cultured for 4 months with weekly
passages at 6,000 cells per cm2, exceeding 12 passages (Fig. 5a).
Transduction of ERpos cells from a different biopsy and sub-
sequent splitting at up to 1:4 supported the robustness of this
approach. Of note, these long-term cultured cells exhibited a
phenotype essentially similar to cultures with deﬁnitive lifespan,
including a relatively high level of ER expression (Supplementary
Fig. 11 and Table 2). Thus, while the proliferation of ERpos cells
with deﬁnite lifespan is somewhat slow as it took more than 100
days to generate more than 25 population doublings, the present
protocol nevertheless allows a considerable expansion of the
ERpos cell population extending from low-passage cultures with
low seeding density through medium-passage cultures with high
seeding density to high-passage cultures of hTERT/shp16-tran-
duced cells, which provides a relatively wide window of experi-
mentation. Of note, until senescence the cells maintain their
expression of ER, Ks20.8 reactivity as well as—mainly in densely
packed colonies—expression of PR (Fig. 5b). In conclusion,
TGFbR2i readily supports serial subculture of a population of
ERpos HBECs, that is, ERpos progenitors.
ERpos progenitors respond to oestrogen. As an ultimate test for
a physiologically relevant ER expression we decided to assess the
effects of added cognate ligand, that is, oestrogen (b-oestradiol).
Accordingly, ERpos cells were exposed to 10 8M of b-oestradiol
or vehicle. The effect of oestrogen was tested in the absence
of epidermal growth factor (EGF) since the transcriptional
activation of ER can be induced by EGF-induced MAP kinase
activity36. As a ﬁrst indication of a functional ER, a higher focal
expression of PR protein, a downstream target of ER signalling,
was seen in the presence of oestrogen (Fig. 6a). Low-passage
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Figure 5 | TGFbR2i allows efﬁcient expansion of ERpos cells. (a)
Population doublings as a function of passage number calculated by
continuous cell number recordings in triplicate cultures before conﬂuency
and plating at a ﬁxed number of 4,000 cells per cm2 per ﬂask at each split.
TGFbR2i allows proliferation for up to six passages, corresponding to 15
population doublings (open diamond). If RepSox is omitted, the cells cannot
be expanded beyond fourth passage (cross). Initial plating on 3T3 feeders
with quantiﬁcation starting in passage three extends proliferation to more
than 10 passages, corresponding to more than 25 population doublings
(open circle). Cells from a different sorting (albeit followed for a shorter
period) exhibit similar extended proliferative capacity (closed circle).
hTERT/shp16-transduced CD166high/CD117low cells subsequently passaged
at a ﬁxed number of 6,000 cells per cm2 at each split extended the
proliferative capacity even further (closed triangle), and the cells have now
been growing for more than 12 passages. hTERT/shp16-transduced
CD166high/CD117low cells derived from a different biopsy, split at a ratio of
up to 1:4, has so far been growing up to passage 9 (open square). (b) Even
beyond 20 population doublings (passage 9), ERpos cells with deﬁnitive
lifespan maintain ER and PR expression as shown by immunoperoxidase
and haematoxylin staining (cells in ninth passage seeded at 4,000 cells per
cm2 and stained at day 5 with SP1 prediluted and SAN27, respectively).
Scale bar, 50mm.
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cultures (passage 2–4) were exposed to oestrogen or vehicle, and
the cell number was quantiﬁed. As seen in Fig. 6b, signiﬁcantly
higher cell numbers were recorded in cultures with oestrogen
(Fig. 6b). Medium-passage cultures (passage 5–6) reached by high
seeding density exhibited a similar response, albeit in general
exhibiting a slower growth (Fig. 6b). Likewise, a proliferative
response was observed in high-passage culture of hTERT/shp16-
transduced ERpos cells (passage 7–12; Fig. 6b). That the observed
increase in cell number was indeed due to the speciﬁc effect of
signalling through ER was veriﬁed on addition of the ER
antagonist ICI182,780, which could abolish the effect completely
(Supplementary Fig. 12). Long-term exposure to oestrogen
further augmented the oestrogen response at the transcriptional
level, as indicated by increased expression of PGR and GREB1
(Fig. 6c), as well as at the translational level as observed in 10
preparations from three biopsies tested in passage 2–6
(Supplementary Fig. 13a) with a signiﬁcant overlap in ER and
PR protein expression (Supplementary Fig. 13b). Thus, the
cultured ERpos cells retain their ability to respond to oestrogen in
a physiologically relevant manner. As an alternative approach we
plated ERpos cells on ﬁbroblast feeders, which have been used
previously to reveal an oestrogenic response in mouse mammary
cells37. ERpos cells were plated on conﬂuent ﬁbroblast feeders in
TGFbR2i with or without oestrogen. At day 8, there was a
signiﬁcant increase in cell number with oestrogen as compared
with the control (Fig. 6b). In the presence of ﬁbroblasts, ERpos
cells responded to oestrogen irrespective of the presence of EGF
(Fig. 6b). These data imply that the stromal microenvironment
beyond the inﬂuence of TGFb is important in the regulation of
the growth of ERpos cells.
In conclusion, we have developed a method to isolate, track
and subculture ERpos and oestrogen-responsive cells from normal
human breast.
Discussion
In spite of the fact that there are multiple protocols for enrichment,
long-term cultivation and clonal growth of HBECs, none of them
are able to isolate, track or support the growth of ERpos HBEC.
This led us to screen our antibody repository for antibodies against
human breast antigens eligible for ﬂow cytometry and cell tracking,
and to test whether the reluctant growth of ERpos HBEC in culture
is due to inhibitory TGFb signalling. Our present ﬁndings
demonstrate that ERpos HBECs identiﬁed in situ by a panel of
markers, including PR, AP2b, GATA3, Bcl2, CDw75, N-cadherin
and 67LR, are enriched for in a CD326high/CD271low/CD166high/
CD117low gate, and these cells express an antigen, unexpectedly
decorated by an antibody, clone Ks20.8, originally raised against
cytokeratin 20 (ref. 14). The distinction between ERpos cells, other
luminal cells and basal cells is further supported by their relative
expression of a panel of transcripts.
The prospective isolation and tracking of ERpos single cells
from normal breast tissue hold promises for the future
comparisons between normal, benign and malignant ERpos cells,
which will hopefully shed some light on the evolution and
pathogenesis of the most frequent form of human breast
cancer. Being able to isolate and track the cells, however, would
be of limited value if the ER expression was lost on culture.
It has been anticipated that ERpos normal cells cannot divide and
that this is why HBECs rapidly lose ER expression in culture38.
We show here that ERpos cells can be released from growth
restraint and sustained by TGFbR2i and that ERpos cells
under these conditions can be expanded considerably. These
ﬁndings may represent a paradigm shift in studying ER
expression and function in the breast, in the future no longer
relying exclusively on in vivo rodent models and human breast
cancer cell lines. In addition, we believe the results answer the
long-standing question of whether ERpos cells can self-renew, and
further establishes that ERpos cells can be generated from ERneg
progenitors39–42, here represented by CD117high luminal cells.
Importantly, the response to TGFbR2i is speciﬁc to luminal cells
only, as neither basal cells, ﬁbroblasts nor ERneg normal breast
cell lines are able to switch on ER in response to TGFbR2i. The
fact that ERpos HBECs are here shown to be proliferating is in
favour of the existence of ERpos progenitors. In general, however,
most ERpos HBECs are considered to be close to the base
in the hierarchy35. Thus, as has been hypothesized for breast
cancer hierarchies43, our data could be interpreted in favour of
the existence of bidirectionality also in the normal breast
hierarchy, that is, on appropriate stimuli a subpopulation of
apparently differentiated cells turn out in reality to be facultative
progenitors.
Table 2 | Frequency of ERpos and lineage marker-positive cells as a function of passage number in culture.
Passage # Per cent ERþ cells Per cent K8þ cells Per cent K19þ cells Per cent P63þ cells
2 41/21/24/38/42 100/100/100/ND/100 44/47/100/ND/60 0*/5/0/ND/0*
3 76w/47/22/50z/26 100w/100/100/100z/100 100w/41/62/100z/76 0w/2/0/0z/0
4 77w/26w/28/51w/23 100w/100w/100/100w/100 100w/79w/34/100w/76 0w/0w/0/0w/0
5 29w/72w/39/38/70/37 100w/100w/100/ND/ND/100 79w/100w/48/ND/29/99 0w/0*,w/0*/ND/0*/6
6 66w/27/42/22 100w/100/ND/97 100w/60/ND/69 0w/0*/ND/8
7 54w/28/30/25/24/45w 100w/100/ND/100/96/NDw 100w/69/ND/63/94/NDw 0w/0*/ND/3/6/10w
8 57w/22/34/18/45w 100w/100/100/100/NDw 100w/78/100/55/85w 0w/0/0/0/12w
9 52w/19/28/87 100w/100/100/100y 100w/100/100/14 0w/0/0/0
10 19 ND ND ND
ND, not done.
The numbers in black (roman font; not bold, italic or underlined entries) indicate low-density split, B4,000 cells per cm2.
Bold entries indicate high-density split, B8,000–20,000 cells per cm2.
Italic entries denote cells with extended lifespan on initial cultivation in BBMYAB and mouse feeders.
The entries that are underlined denote hTERT/shp16-transduced cells.
The percentage of ERpos and lineage marker-positive cells evaluated after immunoperoxidase staining of cultures and counterstained with haematoxylin. Aside from staining for ER (SP1, prediluted), the
lineage markers included luminal keratin K8 (stained by M20 or TS1) and keratin K19, and myoepithelial P63. Each number refers to the frequency of stained cells among a total of 1,000 cells in randomly
selected ﬁelds in a culture representing one biopsy. Cells were counted by use of a  25 objective and a  10 ocular equipped with a grid. Note that cultures remain essentially ERpos and luminal like. At
the onset of senescence (starting at passage 4 in low-density split cultures and up to passage 6–9 in high-density split cultures) there is a tendency for the ER staining to fade out. High-density cultures
from two biopsies maintained a high ER expression on omission of EGF and addition of E2.
*Very few, small foci or individual cells.
wEGF omitted, E2 added.
zþ E2 in passage 1.
yStained in passage 11.
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The release of ERpos HBECs in culture by TGFbR2i is clinically
relevant because it may help explain an enigmatic difference
between the normal human breast and breast cancers. Thus, in the
normal breast in vivo there is a strict dissociation between steroid
receptor expression and proliferation15. In breast cancer and to a
varying degree in precancerous breast lesions this negative
association is lost44. It has been speculated that this may
represent an important early change in the genesis of breast
cancer either reﬂecting a failure to downregulate ER as cells enter
the cell cycle or a failure to suppress division of ERpos cancer cells44.
Our data indeed are in favour of the latter possibility because ERpos
HBECs do divide if TGFb signalling is perturbed, a very likely
scenario in cancer (for review see ref. 45). While in primary breast
cancer a normal-like TGFb signalling is still in operation to restrain
growth, in metastatic breast cancer TGFb signalling has shifted to
that of an epithelial–mesenchymal transition response45.
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Figure 6 | ERpos cells in culture respond to oestrogen. (a) Staining of PR (SAN27) in second-passage CD166high cells deprived of EGF and exposed to
vehicle (EtOH) or oestrogen (E2) for 10 days. ERpos cells respond to oestrogen by increased expression of PR. (b) Quantiﬁcation of cell number in four sets
of pairwise triplicate cultures of EGF-deprived, oestrogen-stimulated CD166high low-passage cells grown for 4 days in second (P959) or third passage
(P958), or 13 days in fourth passage (P959); medium-passage cells grown at high density before growth for 6 days (P958), 15 days (P957) and 14 days
(P957 cultured without EGF since second passage) in ﬁfth passage or cells with extended lifespan grown for 14 days in sixth passage; or high-passage cells
(hTERT/shp16) in seventh passage grown for 13 days or in tenth to twelfth passage grown for 11, 15 and 11 days, respectively, in the presence of oestrogen
(dark grey) or vehicle (light grey); or pairwise triplicate cultures of CD166high cells plus feeder grown for 8 days in the presence of oestrogen (dark grey) or
vehicle (light grey). Second-passage cultures derived from two different biopsies (ﬁrst and fourth set of bars) do not respond differently from third-passage
cultures (second set of bars), irrespective of omission of EGF from TGFbR2i before co-culture (second set of bars)). Omission of EGF throughout the entire
experimental period reduced the total cell number, but did not augment the response to oestrogen (third set of bars). Error bars indicate s.d.’s. In all cases,
oestrogen treatment signiﬁcantly increases the growth of ERpos cells, independent of passage group (by analysis of variance (ANOVA), Po0.05). The
difference between experimental and control in each passage group is statistically signiﬁcant by paired t-test (P values in each diagram). (c) Relative
expression in triplicate of PGR and GREB1 from second (P957 and P959) and third passages (P958), or fourteenth passage long-term (hTERT/shp16)
cultured ERpos cells exposed to vehicle (EtOH, grey bars) or oestrogen (E2, black bars) for 4 (P958 and P959), 22 (P957) or 13 (hTERT/shp16) days,
respectively. Transcription of downstream target genes of ER signalling, PGR and GREB1 is in all cases signiﬁcantly upregulated by oestrogen as assessed by
two-tailed t-test, Po0.05. Error bars indicate s.d.’s.
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Another implication of the TGFbR2i culture protocol is that it
represents a much-in-demand cell-based assay for oestrogen
action on normal cells. It is already well established that oestrogen
is a mitogen for ERpos breast cancer. However, its role in relation
to ERpos HBECs has remained a mystery due to lack of ERpos cell
culture models, and because ectopic expression of ER in basal cell
lines under standard culture conditions has provided the
paradoxical result of growth inhibition11,12. As a proof of
principle, we here show that the TGFbR2i protocol serves as a
physiologically relevant cell-based assay for oestrogen action, and
moreover, in ERpos cells, several oestrogen-responsive genes
downstream of ER are upregulated. Thus, the TGFbR2i protocol
represents a cell-based assay for gauging oestrogen action
reminiscent of its action in vivo. Intriguingly, in the presence of
ﬁbroblasts, growth of ERpos HBECs is stimulated by oestrogen
irrespective of the presence of EGF. This implies that stromal
factors modulate ER activity. With the relevant representatives of
ERpos cells in hand, the complexity of this interaction can now be
elucidated.
Our data further suggest that TGFb signalling is key to the
CD166high phenotype, and the exact mechanisms by which
TGFbR2i generate ERpos cells clearly await further scrutiny. It
cannot be excluded, however, that what we observe is part of a
more general association between CD166 expression and TGFb
signalling. Thus, very recently others have found that TGFb
signalling is a main driver of the behaviour of CD166-expressing
prostate cells46.
The present protocol is the result of several years of
experimentation including many reduction mammoplasties from
different donors until the present conditions were established. We
cannot exclude that further improvements are possible. The data
illustrate, however, that apparent post-mitotic cells in vivo, given
the right conditions may multiply considerably, yet still exhibiting
a deﬁnitive lifespan, and the approach moreover serves as a
platform for extending the lifespan of ERpos cells into serial
subculture.
While we have reproducibly recovered and propagated ERpos
cells from all biopsies tested, we nevertheless wish to emphasize
on a number of technicalities, which should be carefully observed
when the protocol is applied. Biopsies inherently vary with
respect to the frequency of ERpos cells5, which may eventually
inﬂuence the deﬁnite number of ERpos cells that can be derived
from a given biopsy. Biopsies also vary with respect to growth
potential, but in our hands they all perform well up to at least
passage 4 (Table 2). It should be kept in mind, however, that the
protocol releases only a minority of the total number of initially
quiescent ERpos cells, that is, up to 0.54% when plated at 4,000
cells per cm2 on sorting. Also, we strongly recommend that any
attempts to validate Ks20.8 as well as co-expression of ER and PR
by multicolour immunoﬂuorescence are accompanied by
immunoperoxidase staining to unravel the true overlap in
staining. This is particularly important because we found that
tracking of ERpos HBECs in smears must rely on either the ER/PR
antibody mixture or the Ks20.8 surrogate marker speciﬁcally
combined with the ER ﬁxation protocol. Last, we would like to
draw the attention to the fact that while the cultured CD166high/
CD117low cells for the major part retain an elaborate proﬁle of
ERpos cells in situ, they may—again somewhat dependent of the
biopsy of origin—display focal traits of basal or myoepithelial
cells, such as p63, concurrently with luminal traits (Table 2).
That said, there are multiple implications of the present
protocol. First, knowledge about how to turn on and off the ER
expression in non-malignant breast epithelial cells may offer an
alternative to selective oestrogen receptor modulators in preven-
tion of breast cancer in women with elevated risk of disease47.
Second, a reproducible source of normal human ERpos HBECs
will represent a ﬁrst step towards a physiological, cell-based
screen for environmental oestrogenic activity and susceptibility of
normal cells to breast cancer48. And third, the protocol may serve
to test the functional role of recently identiﬁed single-nucleotide
polymorphisms associated with increased risk of breast cancer49.
In conclusion, we have provided a cell-based assay that allows
normal breast ERpos cells to present themselves for investigation.
These ﬁndings may fuel future advances in breast cancer
prevention.
Methods
Tissue. Normal breast biopsies were collected with consent from women
undergoing reduction mammoplasty for cosmetic reasons. The use of human
material has been reviewed by the Regional Scientiﬁc Ethical Committees
(Region Hovedstaden) and approved with reference to H-2–2011–052. Normal
breast tissue was prepared as described25. In brief, normal breast specimens
were minced with opposing scalpels and treated overnight at 37 C with rotation
in collagenase (Type 3, Worthington Biochemical Corporation, 900Uml 1 in
DMEM/F-12 (Life Technologies, catalogue no. 21041) with 2mM glutamine
(Sigma, G7513) and 50 mgml 1 gentamycin (Biological Industries)) before
differential centrifugation to aspirate dissolved fat and to isolate epithelial
organoids and ﬁbroblasts. These were then either used directly or frozen in liquid
nitrogen for later use.
Fluorescence-activated cell sorting. To reveal epithelial cell composition and to
isolate single cells, organoids from 13 biopsies were trypsinized, ﬁltered through a
100-mm ﬁlter and resuspended in HEPES buffer supplemented with 0.5% BSA
(bovine fraction V; Sigma-Aldrich) and 2mM EDTA (Merck), pH 7.5. The sus-
pended cells were incubated for 45min at 4 C in the presence of conjugated
monoclonal antibodies EpCAM/CD326-PerCP cy5.5 (9C4, 1:20, BioLegend),
NGFR (neurotrophin receptor, p75)/CD271-APC (ME20.4, 1:50, Cedarlane
Laboratories) to separate basal and luminal cells, and activated leukocyte cell
adhesion molecule CD antigen, ALCAM/CD166-AF488 (3A6, 1:20, AbD Serotec)
and C-Kit/CD117-PE (104D2,1:20, BD) to separate luminal cells into luminal
ERneg (CD166low/CD117high) cells and luminal ERpos (CD166high/CD117low) cells.
On incubation, the cells were washed twice in HEPES/BSA/EDTA buffer and
ﬁltered through a 20-mm ﬁlter cup (Filcons) to prevent clogging of the FACS
apparatus. Propidium iodide (Invitrogen) was added at a concentration of
1 mgml 1, and the cells were analysed and sorted using a ﬂow cytometer (FAC-
SAria; BD Biosciences). An alternative way to isolate the two luminal subpopula-
tions is to incubate for 30min with EpCAM/CD326-PerCP cy5.5 and ALCAM/
CD166-AF488 along with 67 kDa Laminin Receptor (MLuC5 1:50, Abcam) fol-
lowed by 20min incubation with secondary antibody Alexa Fluor 647 Goat Anti-
Mouse IgM (1:500, Life Technologies).
To detect TGFb receptors on the cell surface, third-passage CD166high/
CD117low cells were incubated with monoclonal antibody TGFbRII (MM0056–
4F14, 1:20, Abcam) followed by secondary antibody AF488 (IgG1, 1:500) and
analysed by FACS. Overlay histograms were produced using Flowing Software 2.5.1
(University of Turku, Finland).
To establish ﬁbroblast feeders, fourth-passage ﬁbroblasts were incubated as
described above with monoclonal antibodies CD26 (202–36, 1:200, Abcam) and
conjugated CD105-AF488 (1:25, AbD Serotec) followed by secondary antibody
AF647 (IgG2b, 1:500) to isolate CD105high/CD26low cells.
Cell culture. On sorting, the primary cell populations were plated in Primaria T25
ﬂasks (#3813, Becton Dickenson) in the presence of ‘FAD2’ ((DMEM, high glucose,
no calcium, Life Technologies):Ham’s F12 Nutrient Mixture (F12, Life
Technologies) 3:1 v/v) with 2mM glutamine, 0.5 mgml 1 hydrocortisone,
5 mgml 1 insulin, 10 ngml 1 cholera toxin (Sigma-Aldrich), 10 ngml 1
epidermal growth factor (Peprotech), 1.8 10–4M adenine, 10mM Y-27632
(Y0503, Sigma-Aldrich or 1683, Axon Medchem) and 5% fetal bovine serum
(Sigma-Aldrich), modiﬁed from refs 26,27). On plating, which could take up to 2
days for the luminal ERneg (CD166low/CD117high) cells and thus determined the
time point for addition of TGFbR2i, a combination of the selective inhibitor of
TGFb type I receptor activin receptor-like kinase ALK5, ALK4 and ALK7,
SB431542 (ref. 50) (10 mM, S4317, Sigma-Aldrich or 1661, Axon Medchem) and an
inhibitor of autophosphorylation of ALK5, RepSox51,52 (25 or 50mM, R0158,
Sigma-Aldrich) was added. To test the speciﬁcity of the effect of TGFbR2i, in some
experiments SB431542 alone or the double concentration of SB431542 was used
instead of TGFbR2i, or RepSox was replaced by another TGFb type I receptor
activin receptor-like kinase ALK5 inhibitor, SD208 (1 mM, Tocris Bioscience). The
vehicle, dimethyl sulfoxide (Sigma-Aldrich), was included in all experiments in
appropriate concentrations for control cultures. Gentamycin (50 mgml 1,
Biological Industries) was added to the cultures throughout the ﬁrst week after
sorting, otherwise antibiotics were not included. To address whether propagation
of ERpos cells was restricted to the FAD2 medium, CD166high/CD117low cells
sorted from one of the biopsies were plated at a density of 4,000 cells per cm2 on
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Primaria six-well in either FAD2, M87A28, MEGM (LONZA) or WIT-P-NC
(STEMGENT) medium including cholera toxin (100 ngml 1) (ref. 53) and the
cultures were observed for plating for 3 days. The possible induction of ER by
TGFbR2i in other breast cells was further tested in MCF-10A54, HMT-3522
(ref. 55), ﬁbroblasts puriﬁed from normal breast tissue25, CD117high cells
puriﬁed from three different biopsies, as well as in basal cells isolated by FACS as
described above and cultured on irradiated NIH-3T3 feeders26 before exposure to
TGFbR2i for up to 7 days followed by staining for ER and Ks.20.8. Fibroblasts were
routinely grown to conﬂuency on collagen-coated T25 ﬂasks (Nunc, 8 mg collagen
per cm2, PureColl, CellSystems) in DMEM/F12, with 2mM glutamine and 5% FBS
before co-culture with CD166high/CD117low luminal cells. For phase contrast
microscopy a Nikon Diaphot 300 microscope was used.
Cloning efﬁciency at low density in FAD2 was observed by plating the sorted
basal cells, and the luminal populations CD166low/CD117high and CD166high/
CD117low, at 400 cells per cm2 and culturing for 14 days, followed by ﬁxation in
methanol for 5min at  20 C and counterstaining of nuclei with haematoxylin.
To assess the Ks20.8 and ER expression of the sorted populations and to further
assess whether starting the culture at a higher density would change the expression,
cells were seeded at 3,000 cells per cm2 and cultured for 9 days before
immunocytochemical staining.
To quantify the frequency of Ks20.8high/ERpos colony-forming units CD166high/
CD117low luminal cells from three different biopsies were plated at a density of
4,000 cells per cm2 with or without TGFbR2i and grown for 13 days before staining
for ER and Ks20.8 followed by quantiﬁcation using an ocular grid. The number of
stained colonies deﬁned as presence of either marker in three areas of each culture
relative to the initial number of seeded cells was calculated.
Low-density split cultures were initially seeded at 6,400 cells per cm2 and grown
for up to 15 days in primary culture in TGFbR2i or with SB431542 alone. Next, the
cultures were trypsinized and seeded at 4,000 cells per cm2 in triplicate cultures,
and subsequently passaged at the same density before the cultures reached
conﬂuency. Parallel cultures were stained to assess Ks20.8, ER and PR expression
status. The number of cells was quantiﬁed manually using a counting chamber.
Medium-passage cultures were passaged at high seeding density, that is,
8,000–20,000 cells per cm2. For extended cultivation of low-density cultures sorted
luminal Ks20.8pos/ERpos (CD166high/CD117low) cells were ﬁrst allowed to
form colonies on irradiated NIH-3T3 feeders in modiﬁed breastoid base medium
(BBM) without HEPES56 (DMEM/F12 supplemented with glutamine, 100 mM
ethanolamine (Sigma , E0135), 1 mgml 1 hydrocortisone (Sigma, H0888),
9 mgml 1 insulin (Sigma, I6634), 5 mgml 1 transferrin (Sigma, T1147),
5.2 ngml 1 selenous acid (sodium salt, BD Biosciences, 354201), 20 ngml 1
basic ﬁbroblast growth factor (Peprotech, 100-18B) and 5nM amphiregulin
(R&D Systems, 262-AR-100/CF)) with the addition of Y-27632, adenine and the
serum replacement B27 (20 ml ml 1, Life Technologies), and subsequently sorted
by FACS on incubation with CD326 and CD271 as described above to isolate
CD326high/CD271high cells before plating and passaging in TGFbR2i culture.
Population doublings were calculated as n¼ 3.32(log UCY log I)þX,
where n¼ population doubling, UCY¼ cell yield, I¼ inoculum number and
X¼ population doubling rate of inoculum.
To determine whether continuous TGFbR2i culture was needed to sustain ER
and Ks20.8 expression, cells in the sixth passage were switched to FAD2 and the
number of ERpos cells (n¼ 3 100) was compared with parallel TGFbR2i cultures
at day 3 and 5. Three similar experiments were performed with cloned hTERT/
shp16-transduced cells (please see below).
As an alternative approach to extend the lifespan of Ks20.8pos/ERpos cells, the
method by Kiyono et al.57 was adapted by introducing human telomerase (hTERT)
and shRNA p16 (shp16) to second-passage CD166high/CD117lowcells. The viral
constructs, pLENTi X2 Hygro/shp16 (w192–1, AddGene #22264, a gift from Eric
Campeau) and pBABE-neo-hTERT58 (AddGene #1774, a gift from Robert
Weinberg) were prepared as follows: lentiviral particles containing the shp16
construct were generated by transient co-transfection into HEK-293T cells using
the calcium phosphate method with the vesicular stomatitis virus glycoprotein
expressing construct pCMV–vesicular stomatitis virus glycoprotein as well as pol–
gag construct pLP1 and rev construct pLP2. Retroviral hTERT particles were
generated by transient co-transfection of the vector construct into a pantropic
retroviral packaging cell line GP2–293 (Clonetech), which stably expresses the
retroviral gag–pol genes. Medium was changed B16 h after transfection and viral
media was collected B48 h later and stored at 4 C for further puriﬁcation. High-
titre stocks of the virus were puriﬁed using a 20% sucrose gradient during
ultracentrifugation with a Beckman SW32Ti rotor at 25,000 r.p.m. for 1.5 h.
Puriﬁed viral solution was stored at  80 C.
Before transduction, the cells were ﬁrst treated with 200mUml 1
neuraminidase (N7885, Sigma) for 2 h at 4 C, and then transduced using a high-
viral titre59 containing the pBABE-neo-hTERT construct in TGFbR2i without FBS
and incubated at 37 C in 5% CO2 overnight. The culture medium was changed
and the transduced cells underwent antibiotic selection for 10 days with
500mgml 1 G418 (Life Technologies). On conﬂuency, the cells were passaged
and underwent an identical transduction procedure with viral particles containing
the pLenti X2 Hygro/shp16 construct and subsequent antibiotic selection with
100mgml 1 hygromycin (Sigma) for more than 2 weeks. The efﬁciency of
the protocol was conﬁrmed by hTERT/shp16 transducing second-passage
CD166high/CD117low/Ks20.8pos/ERpos cells derived from a different biopsy.
To test the proliferative response to oestrogen in low-passage (p2–4) cultures,
ERpos cells in TGFbR2i culture were seeded with 4,000 cells per cm2 in TGFbR2i
with 25mM RepSox and without EGF, supplemented with oestrogen (10–8M,
b-oestradiol, E2758, Sigma-Aldrich) and cultured for up to 13 days with medium
change every other day. A primary culture from another biopsy was cultured 27
days in the presence of oestrogen and without EGF before splitting. The cells were
passaged at 4,000 cells per cm2 in triplicate cultures with oestrogen or vehicle
(96% ethanol). At day 4, the cultures were trypsinized and quantiﬁed using
a counting chamber. Medium-passage (p5–6) cultures were passaged at
10,000–20,000 cells per cm2 before seeding at 4,000 cells per cm2, and the
high-passage (p7–12) cultures including two hTERT/shp16-transduced
populations derived from separate biopsies were passaged at 6,000 cells per cm2
or split at up to 1:4 before the growth experiment with a seeding density
of 6,000 cells per cm2. The effect of an oestrogen antagonist (ICI182,780,
Sigma-Aldrich), was tested in sixteenth passage, single-cell-cloned hTERT/
shp16-transduced cells seeded at 4,000 cells per cm2 in TGFbR2i exposed to
vehicle or oestrogen (10–10M) and increasing concentrations of ICI182,780
(10–10, 10–9 and 10–8M). At day 6, cultures were trypsinized and quantiﬁed
in a cell counter (Roche Innovatis).
To assess whether the response of ERpos cells to oestrogen was modulated
by the presence of ﬁbroblasts, second- or third-passage ERpos cells, with or
without the omission of EGF in the previous passage, were plated at a
density of 5,600 cells per cm2 on conﬂuent ﬁbroblast feeders in triplicate
culture. The following day, the culture medium was switched to TGFbR2i
with oestrogen or vehicle. Under these conditions, ﬁbroblasts did not grow.
At day 8, the cultures were trypsinized and the total cell number was quantiﬁed.
Whether a continuous lack of EGF inﬂuenced the response to oestrogen was
tested in a similar set-up, where EGF was omitted from the medium during
the entire experimental period.
The long-term effect of oestrogen on ER and PR expression in cultures without
EGF was tested in 10 preparations of pairwise cultures in passage 2–6 derived from
three different biopsies. The cultures were grown up to 26 days with oestrogen and
vehicle, respectively, and subsequently stained by immunoperoxidase or
immunoﬂuorescence (see below).
RNA extraction and qRT–PCR. Total RNAs from sorted normal primary cells
from eight biopsies were extracted using Trizol (Invitrogen) and were reverse
transcribed using the High Capacity RNA-to-cDNA Kit (Applied Biosystems). For
general gene expression proﬁling, 2 ng of total cDNA was used to perform
quantitative real-time PCR using the TaqMan Gene Expression Assays (Applied
Biosystems) on CFX384 Touch Real-Time PCR Detection System (Bio-Rad). The
primers are listed in Supplementary Table 1, and real-time PCR conditions were the
following: 50 C for 2min and 95 C for 10min, followed by 40 cycles at 95 C for
10 s and 60 C for 30 s. To quantify cDNA concentration represented by cycle
threshold (Ct) values, Cts were determined at the initial period of exponential
ampliﬁcation in triplicates and the different PCR runs were adjusted by inter-run
calibrators (Bio-Rad CFX manager 3.0). Each gene expression level was to the mean
of four reference gene expressions (GAPDH, HPRT1, TBP, and TFRC). The
qRT–PCR data were then visualized as a heatmap using the statistical programme R
(ref. 60) or as a bar graph using the values calculated by the 2DDCt method61. For
qRT-PCR of ER, K8, FOXA1, ELF5 and K18, second-passage cultures of CD166high
cells at a density of 8,000 cells per cm2 in FAD2, SB431542 or SB431542 switched to
TGFbR2i culture conditions for 5 days before RNA extraction were used.
The expression of ER signalling and its downstream target genes were analysed
in CD166high cells with or without TGFbR2i by using a RT2 Proﬁler PCR array
(human oestrogen signalling, Qiagen) according to the manufacturer’s instructions.
Total 4 mg of RNA was used per array, which was performed in duplicates from two
different biopsies. Three sets of E2- or ethanol (vehicle)-treated second- or third-
passage ERpos cells or hTERT/shp16-transduced cells were further analysed in
triplicate for PGR and GREB1 expression with the TaqMan Gene Expression
Assays in the same condition mentioned above, using 20 ng of cDNA in each
PCR reaction.
Western blotting. Whole-cell lysates were prepared for extraction by incubation
in RIPA lysis buffer for 30min at 4 C with protease inhibitor cocktail (P8340,
Sigma) and phosphatase inhibitor cocktail (Sigma, P5726). Proteins were
separated by a 4–12% Novex Bis-Tris pre-cast polyacrylamide gradient gel (Life
Technologies) and transferred to a polyvinylidene diﬂuoride membrane using iBlot
dry blotting system (Life Technologies). Molecular weight was indicated by using a
pre-stained protein ladder (SM0671, Fermentas). After blocking 1 h in room
temperature, the membrane was incubated with primary antibodies recognizing
Smad2/3 (1:1,000, #3102, Cell Signaling), pSmad 2 (1:1,000, #3101, Cell Signaling),
b-actin (1:5,000, A-5441, Sigma) or ER (1:500, NCL-ER-6F11/2, Novocastra) in
blocking solution with gentle rocking overnight at 4 C. Secondary antibodies
conjugated with horseradish peroxidase (Dako) were incubated for 1 h at room
temperature. Western blots were visualized using enhanced chemiluminescence
solution (PerceECL 32106, Thermo Scientiﬁc) and a chemiluminescence imager
(Amersham Image 600, GE Healthcare life sciences).
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Immunohistochemistry and cytochemistry. Cryostat sections, smears of sorted
cells and monolayer cultures were prepared and stained by immunoperoxidase
or immunoﬂuorescence, including negative controls without primary
antibodies3,22,62. Speciﬁcally, cellular smears for ER–PR staining were ﬁxed in 4%
paraformaldehyde (Electron Microscopy Sciences) followed by ﬁxation in ice-cold
methanol:acetone (1:1) for 10min at  20 C. Smears were then washed two times
for 3min and blocked for 10min in 0.5% saponin (Sigma)/10% goat serum in PBS.
All subsequent washing and incubation steps were performed in 0.5% saponin/10%
goat serum. To visualize hormone receptor expression smears were incubated with
anti-ER (SP1, 1:10) and anti-PR (SP2, 1:10) for 2 h at room temperature followed
by 30min with Alexa Fluor 568 Goat anti-Rabbit IgG (1:500, Invitrogen). For
quantiﬁcation of ER–PR and Ks20.8 expression, smears were ﬁxed as described
above and subsequently incubated with anti-ER (SP1, 1:10), anti-PR (SP2, 1:10)
and Ks20.8 (1:10) for 2 h at room temperature followed by incubation for 30min
with Alexa Fluor 568 Goat anti-Rabbit IgG (1:500, Invitrogen) and Alexa Fluor 488
Goat anti-Mouse IgG2a (1:500, Invitrogen). Slides were mounted with ProLong
Gold antifade reagent with 4,6-diamidino-2-phenylindole (DAPI; Life
Technologies), and quantiﬁcation of stained smears was routinely based on 3 100
cells, directly observed or evaluated in random micrographs obtained with a  20
objective in the confocal microscope.
Antibodies are listed in Table 1. Many antibodies stain independently of
ﬁxation procedure, but of note, to stain for ER and PR, cultures were rinsed in PBS,
pH 7.4, or sections were air dried before ﬁxation, for 5min at room temperature, in
3.7% formaldehyde, two rinses in PBS, ﬁxation in methanol:acetone (1:1) for 5min
at 20 C, two rinses in PBS, permeabilization in 0.1% Triton X-100 in PBS, twice
for 7min, rinse in PBS and kept wet before application of UltraV Block (Thermo
Scientiﬁc). ER and PR expression in cultures with long-term oestrogen exposure
was assessed by immunoperoxidase for ER (SP1, prediluted) and PR (SAN27 or
PgR636) or by double-labelling immunoﬂuorescence for ER (SP1, 1:10) and PR
(PgR636, 1:10) with Alexa Fluor 488 Goat anti-Rabbit IgG (1:500) and Alexa Fluor
568 Goat anti-Mouse IgG1 (1:500) as secondary antibodies.
To stain for K15, UltraV Block was substituted for 10% normal goat serum in
PBS. Immunoﬂuorescence and peroxidase stainings were evaluated, quantiﬁed and
photographed using a laser-scanning microscope (LSM 510 or LSM700; Carl Zeiss
MicroImaging, Inc.) and bright-ﬁeld microscopes (Laborlux S or DM5500B, Leica),
respectively. For quantiﬁcation of immunoperoxidase staining of ER, K8, K19 and
p63, nuclei were counterstained with haematoxylin and counted in randomly
selected ﬁelds using an ocular grid and given as the percentage of stained cells of a
total of 1,000 cells evaluated with a 25 objective.
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